Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
VXRT Vaxart
- 0.4472
- +0.0465+11.60%
Close Apr 28 16:00 ET
- 0.4762
- +0.0290+6.48%
Post 19:58 ET
102.05MMarket Cap-1.36P/E (TTM)
0.4777High0.4300Low5.45MVolume0.4382Open0.4007Pre Close2.47MTurnover2.41%Turnover RatioLossP/E (Static)228.21MShares1.070052wk High1.73P/B101.25MFloat Cap0.285052wk Low--Dividend TTM226.41MShs Float24.9000Historical High--Div YieldTTM11.90%Amplitude0.2543Historical Low0.4530Avg Price1Lot Size
About Vaxart Company
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.
Company Profile
SymbolVXRT
Company NameVaxart
Listing DateDec 1, 1969
Issue Price8.00
Founded2004
CEOMr. Steven Lo
MarketNASDAQ
Employees105
Fiscal Year Ends12-31
Address170 Harbor Way,Suite 300
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-550-3500
Websitehttp://www.vaxart.com
Company Executives
- Name
- Position
- Salary
- Steven Lo
- Director, President and Chief Executive Officer
- 2.09M
- Phillip E. Lee
- Chief Financial Officer and Principal Accounting Officer
- --
- James F. Cummings
- Chief Medical Officer
- 1.21M
- Dr. Sean N. Tucker, PhD
- Senior Vice President and Chief Scientific Officer
- 1.16M
- Edward B. Berg
- Senior Vice President and General Counsel
- --
- Dr. Michael J. Finney, PhD
- Chairman of the Board
- 305.39K
- Kevin P. Finney
- Independent Director
- --
- W. Mark Watson
- Independent Director
- 142.88K
- Dr. Elaine J. Heron, M.B.A.,PhD
- Independent Director
- 143.78K
- Dr. David E. Wheadon, M.D.
- Lead Independent Director
- 146.98K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call